Marathon Patent Group, Inc. Announces that the USPTO has Denied Toyota Motor Corporation's Petition Requesting Institution of Inter Partes Review

LOS ANGELES, CA -- (Marketwired) -- 01/06/17 -- Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon" or "Company"), an IP licensing and commercialization company, announced today that on January 5, 2017, the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") issued a ruling denying the IPR2016-01382 petition filed by Toyota Motor Corporation ("Toyota") against U.S. Patent No. 5,732,375 ("375 Patent").

The '375 patent is assigned to Signal IP, Inc. ("Signal"), a wholly-owned subsidiary of Marathon Patent Group.

The '375 patent has been asserted against Toyota in the U.S. District Court for the Central District of California ("CACD"), Case No. CACD-2-15-cv-05162.

"We are pleased with the USPTO's decisions denying Toyota's IPR petition," said Doug Croxall, CEO of Marathon Patent Group. "These rulings, along with those that have preceded it, continue to demonstrate the value of our proprietary process to assess, value, and acquire high quality patent assets that have the potential of generating meaningful return on investment for both the company and its shareholders."

About Marathon Patent Group, Inc.

Marathon is an IP licensing and commercialization company. The Company acquires and manages IP rights from a variety of sources, including large and small corporations, universities and other IP owners. Marathon has a global focus on IP acquisition and management. The Company's commercialization division is focused on the full commercialization lifecycle which includes discovering opportunities, performing due diligence, providing capital, managing development, protecting and developing IP, assisting in execution of the business plan, and realizing shareholder value.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, but not limited to, the amount and use of proceeds the Company expects to receive from the sale of the shares of common stock in the registered direct offering and the closing of the transactions. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate, and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Risk Factors" in the Company's Annual Reports on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

CONTACT INFORMATION

Marathon Patent Group
Jason Assad
678-570-6791
Email Contact

Source: Marathon Patent Group

Released January 6, 2017